Relationship Between Neurotransmitter Receptor Polymorphisms, Plasma Concentrations and Clinical Response to Clozapine

Completed

Conditions studied: Schizophrenia

In brief

This is a study designed to identify genetic polymorphisms (also called allelic variants or genetic markers) that are associated with response to clozapine. This information will be used to enhance the understanding of clozapine response and side effects. DNA from patients will be examined for significant associations between allelic variants in candidate genes in relation to clozapine effects on positive and negative symptoms, global response, quality of life, relapse rates and side effects.

Key facts

Study ID

NCT00581932

Run by

Delwyn D. Miller

People needed

76

Starts

2001-10-01

Expected to finish

2015-12-01

Last updated by the study team

2017-05-12

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of schizophrenia
• Beginning clozapine therapy
• age 18-65
• must be willing to participate in interviews and provide a DNA sample

You may not qualify if…

• no longer taking clozapine

Where it is running

• University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.